Skip to main content

ADMA Biologics Value Stock - Dividend - Research Selection

ADMA Biologics

ISIN: US0008991046, WKN: A12FAG

Market price date: 25.09.2020
Market price: 2,18 USD




ADMA Biologics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 07-09-2020
Cash flow
Net operating cash flow -76.193.500
Capital Expenditures -3.811.840
Free cash flow -80.005.344
Balance sheet
Total Equity 26.193.100
Liabilities & Shareholders equity 127.091.000
Income statement
Net income -48.279.300
Eps (diluted) -0,890
Diluted shares outstanding 54.800.600
Net sales/revenue 29.349.100

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C -1,57
   
P/FC -1,49
Balance sheet
ROI-37,99
ROE20,61
Income statement
P/E-2,45
Div. Yield0,00%
P/B4,56
P/S4,07


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolADMA
Market Capitalization119.465.312,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internethttp://www.admabiologics.com


Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.admabiologics.com